AI Article Synopsis
- The study investigates the best methods for preventing hepatitis B virus (HBV) recurrence after liver transplantation in HBV-infected patients, comparing a combination of hepatitis B immunoglobulin (HBIG) and high-potency nucleos(t)ide analogues (HPNAs) versus HPNAs alone.
- Using a systematic review and meta-analysis, researchers analyzed data from 16 studies with 7,897 patients and found similar rates of HBV recurrence and overall survival between the two treatment strategies after liver transplantation.
- The results suggest that HPNAs monotherapy (particularly entecavir) is as effective as the combination with HBIG, potentially alleviating concerns about the safety and efficacy of using HPNAs alone for long
Article Abstract
Background: The optimum prophylactic regimen against hepatitis B virus (HBV) recurrence after liver transplantation (LT) in HBV-infected patients is uncertain but of great clinical relevance. New evidence suggests that hepatitis B immunoglobulin (HBIG)-free approach would become a reasonable choice in the era of high-potency nucleos(t)ide analogues (HPNAs). We aimed to provide robust estimates for long-term survival and HBV recurrence in patients receiving different HBV-prophylaxis strategies after LT.
Methods: We did a systematic review and meta-analysis using both pseudo-individual patient data recovered from included studies (IPDMA) and conventional trial-level aggregate data meta-analysis (ADMA). Hazard ratios (HRs) were calculated using different Cox proportional hazard models accounting for inter-study heterogeneity. ADMA was conducted to pool outcomes at specific time points.
Results: A total of 16 studies involving 7897 patients and 41 studies involving 9435 were eligible for IPDMA and AMDA, respectively. Cumulative HBV recurrence rate and overall survival (OS) at 1, 3, 5 and 10 years post-LT were 0.3%, 0.9%, 1.2%, 1.7% and 95.6%, 89%, 86.4%, 86.4% in the HPNAs (i.e., entecavir and tenofovir) + HBIG combination group vs. 0.6%, 0.6%, 1.2%, 1.7% and 94.5%, 86.8%, 84.8%, 81.2% in the HPNAs monotherapy group (HR 1.20, 95% CI 0.56-2.60, p = 0.64; HR 1.09, 95% CI 0.70-1.69, p = 0.72), respectively. The results were compatible with AMDA.
Conclusion: A similar HBV recurrence and overall survival were found in patients who used HPNAs (mainly entecavir) monotherapy as in those who received a combination of HPNAs and HBIG. These findings address concerns regarding the safety and effectiveness of HPNAs monotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12072-022-10466-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extra X, extra questions: Trisomy X syndrome and IgA deficiency - a case report.
Front Immunol
December 2024
Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
While Trisomy X syndrome is typically characterized by developmental and cognitive variations, it is not commonly associated with immunodeficiencies. We report the unique case of a 6-year-old girl with Trisomy X presenting with selective IgA deficiency, challenging the conventional understanding of this chromosomal condition. The patient exhibited recurrent respiratory infections and gastrointestinal symptoms, evaluated in the context of her genetic background of Trisomy X and significantly low levels of IgA (0.
View Article and Find Full Text PDFright posterior sectionectomy during liver procurement based on preoperative 3D planning to prevent extreme large-for-size syndrome in adult-to-adult liver transplantation: a case report.
Quant Imaging Med Surg
December 2024
Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Background: Large-for-size syndrome (LFSS) is an uncommon but potentially lethal complication following adult liver transplantation (LT). Reduced-size liver transplantation (RSLT) is considered a valuable alternative to delayed fascial closure or mesh closure for preventing LFSS. In this article, we report a successful adult-to-adult RSLT case with right posterior graft sectionectomy using three-dimensional (3D) computer-assisted planning.
View Article and Find Full Text PDFCorrelation between P2-PCA volume flow rate and BOLD cerebrovascular reactivity in patients with symptomatic carotid artery occlusion.
AJNR Am J Neuroradiol
December 2024
From the Department of Neurosurgery (AW., J.F., L.M.H., J.P., M.G., V.S., C.H.B.v.N., L.R., G.E., M.S.), Clinical Neuroscience Center (AW., J.F., L.M.H., J.P., T.S., M.G., V.S., C.H.B.v.N., S.W., A.R.L., Z.K., L.R., G.E., M.S.), Department of Neuroradiology (Z.K.) and Department of Neurology (S.W., A.R.L.), University Hospital Zurich, Zurich, Switzerland; University of Zurich (AW., J.F., L.M.H., J.P., T.S., M.G., V.S., C.H.B.v.N., S.W., A.R.L., Z.K., L.R., G.E., M.S.), Zurich, Switzerland; cereneo Center for Neurology and Rehabilitation (A.R.L.), Vitznau, Switzerland.
Background And Purpose: Identifying and assessing hemodynamic and flow status in patients with symptomatic internal carotid artery (ICA) occlusion is crucial for evaluating recurrent stroke risk. The aim of this study was to analyze the correlation between two quantitative imaging modalities: (1) blood oxygenation level-dependent (BOLD) cerebrovascular reactivity (CVR) and (2) quantitative magnetic resonance angiography (qMRA) with non-invasive optimal vessel analysis (NOVA), measuring volume flow rate (VFR). Comparing these modalities is relevant for assessing collateral circulation and hemodynamic impairment.
View Article and Find Full Text PDFPrognostic utility of gamma-glutamyl transpeptidase to platelet ratio in patients with solitary hepatitis B virus-related hepatocellular carcinoma after hepatectomy.
World J Gastrointest Oncol
December 2024
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Background: The prognostic impact of preoperative gamma-glutamyl transpeptidase to platelet ratio (GPR) levels in patients with solitary hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) following radical resection has not been established.
Aim: To examine the clinical utility of GPR for prognosis prediction in solitary HBV-related HCC patients.
Methods: A total of 1167 solitary HBV-related HCC patients were retrospectively analyzed.
Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis.
Cancer Med
December 2024
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
Background And Aims: The immune microenvironment (IME) plays a crucial role in the progression of hepatocellular carcinoma (HCC). In HCC, the IME is often compromised by hepatitis B virus (HBV) infection, chronic inflammation, and fibrosis. Both antiviral therapy (AVT) and the alleviation of inflammation and fibrosis (AIF) have been shown to improve prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!